Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Phase-appropriate documentation for viral vectors is a dynamic process that aligns with the therapeutic development timeline. An effective strategy begins during early process development, establishing controls and data collection systems that scale from research-grade material to GxP-compliant batches intended for IND-enabling studies. This approach avoids costly rework and de-risks regulatory submissions by ensuring a complete, auditable data package that demonstrates manufacturing consistency and product quality over time.

Aligning Vector Manufacturing with Regulatory Expectations

The data supporting a successful viral vector program extends beyond in vivo efficacy. While preclinical results establish a vector’s therapeutic potential, such as those demonstrating the utility of AAV-based gene replacement for metabolic disorders (PMID: 22505953), regulatory bodies require an equally coherent narrative on manufacturing and controls. The ability to demonstrate regression of atherosclerosis in a preclinical model (PMID: 20976059) is scientifically compelling, but its value in a regulatory submission is directly tied to the quality and consistency of the vector production process.

A forward-thinking documentation strategy anticipates future regulatory scrutiny. It builds a comprehensive data package that connects every stage of development, from the initial plasmid sequence to the final vialed product. This is achieved by implementing systems that capture not just the results, but the context and control behind them.

Building a Foundation for IND Submission

The path from a research-grade AAV, lentivirus, or adenovirus vector to an IND-enabling batch is paved with meticulous data collection. Our approach within our >100,000 sq ft facility is to establish this framework from the outset.

• Raw Material Traceability: Full documentation of the source, identity, and quality of all materials, including plasmids, cell banks, and media components.

• Process Parameter Definition: Identifying and justifying key process parameters during small-scale runs to ensure scalable and reproducible manufacturing.

• Analytical Method Lifecycle: Documenting the development, qualification, and validation of all analytical assays used for product characterization, release, and stability testing.

• Batch Record Integrity: Ensuring that every manufacturing run is supported by detailed and accurate batch records that provide a complete history of the production process.

This structured approach creates a clear and defensible narrative for regulatory agencies. Strategic Documentation Systems Accelerating Audit Readiness. By treating every research batch as a precursor to a GxP batch, we help sponsors build the robust data package needed to achieve their 18-24 month IND timelines. This methodology has been a key contributor to the 100% IND success rate for programs we have supported since 2019, even as the Franklin Biolabs brand itself launched in 2024.